Denovo Sciences submitted a joint manuscript introducing BSA-DB, a new resource for broad-spectrum antiviral discovery with 13194 active compounds.
Public source
Publisher name
Public post
Yesterday, we submitted a joint manuscript from Denovo Sciences and my lab that I believe can make a meaningful contribution to pandemic preparedness. The work introduce…
Company
Denovo Sciences
We are creating novel therapeutics using state-of-the-art proprietary AI technologies.
- Industry
- Biotechnology
- Location
- Yerevan, AM
- Company size
- 11–50 employees
About Denovo Sciences
A deep technology company that creates novel therapeutics using state-of-the-art AI technologies.
See moreLatest activity
Latest activity from Denovo Sciences
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Deep Origin
Deep Origin's computational platform contributed to a study published in Cell, identifying a lead compound from a library of molecular glues and matching results from Stanford and MD Anderson.
Research & Knowledge
Insilico Medicine
Insilico Medicine was featured in a Forbes/BernardMarr.com article by Bernard Marr exploring how the company is moving past early AI proofs-of-concept to build a repeatable, scalable engine for biopharma innovation.
Research & Knowledge
Biocytogen
Biocytogen published a new Nature Biotechnology study reporting AIntibody, a prospective, blinded benchmark testing 511 AI-designed or AI-selected antibodies from 29 organizations with every submission experimentally evaluated for affinity and developability.
Research & Knowledge
Terns Pharmaceuticals
Terns Pharmaceuticals published a recent paper showing that Reinforcement Learning with Metacognitive Feedback (RLMF) improves an AI's ability to signal uncertainty by up to 63% compared to standard methods.
Research & Knowledge
EditCo Bio